About US
Contact us
-
Sanofi to continue developing Prednisporin under sub-licencing agreementSanofi has announced in its latest quarterly financial update that the company intends to continue developing Prednisporin under the terms of a sublicense agreement with a third party. Prednisporin i2012/10/31
-
Organisational structure 'key to pharma compliance'With only a quarter of leading pharmaceutical companies having centralised their compliance departments, new research suggests that organisational structure is crucial to improving these efforts. Acc2012/10/30
-
'Slight decline' in pharmaceutical M&A activityThe last 18 months has seen a slight decline in pharmaceutical merger and acquisition (M&A) activity, following steady levels since 2008, a report has revealed.Research by intelligence firm Irving2012/10/30
-
Canada joins in on Novartis vaccine suspensionAdd Canada to the growing list of countries weighing in against Novartis' ($NVS) flu vaccines.Health Canadasaid it would suspend the shots, following similar moves by European regulators, because of c2012/10/29
-
Pfizer reps to bear brunt of Canadian layoffsMore job cuts at Pfizer ($PFE). The world's biggest drugmaker is shedding 300 from its Canadian workforce, or about 11% of its employees in the country. Hardest hit will be sales and marketing, partic2012/10/29
-
Novo's new insulin Tresiba to face tough questions from FDA panelLast week, the future of Novo Nordisk's newinsulindrug Tresiba looked very bright. Today, not so much.A week ago, theEuropean Medicines Agency(EMA) recommended the long-acting insulin for approval, an2012/10/26
-
Germany, France join crowd withdrawing Novartis vaccinesMuch of the EU crowd has decided to jump on the bandwagon, pulling some of Novartis' ($NVS)flu vaccinesfrom the market because there have been reports of particulates in some vials. No problems have b2012/10/26
-
Italy bans Novartis vaccines even after company assures their safetyItaly is having a difficult time getting flu vaccine. Italian authorities today said they are banning four different Novartis ($NVS) vaccines because of questions over "side effects" less than two wee2012/10/25
-
BMS results crater on 96% drop in Plavix salesBristol-Myers Squibb's ($BMY) third quarter continues the generics-are-poison trend. The company saw sales drop by 30%--yes, 30%--as copycats siphoned off sales from its big-selling blood-pressure dru2012/10/25
-
'Slight decline' in pharmaceutical M&A activityThe last 18 months has seen a slight decline in pharmaceutical merger and acquisition (M&A) activity, following steady levels since 2008, a report has revealed.Research by intelligence firm Irving2012/10/24